Aug 4 (Reuters) - Merck & Co Inc MRK.N :
* MERCK AND HANMI PHARMACEUTICAL ENTER INTO LICENSING
AGREEMENT TO
DEVELOP EFINOPEGDUTIDE, AN INVESTIGATIONAL ONCE-WEEKLY THERAPY
FOR NONALCOHOLIC STEATOHEPATITIS (NASH)
* UNDER AGREEMENT, MERCK WILL BE GRANTED EXCLUSIVE LICENSE
TO
DEVELOP, MANUFACTURE, COMMERCIALIZE EFINOPEGDUTIDE IN US AND
GLOBALLY
* MERCK - DATA FROM PHASE 2 STUDIES HAS PROVIDED COMPELLING
CLINICAL EVIDENCE THAT WARRANTS FURTHER EVALUATION OF
EFINOPEGDUTIDE FOR TREATMENT OF NASH
* HANMI WILL RECEIVE UPFRONT PAYMENT OF $10 MILLION & IS
ELIGIBLE
TO RECEIVE MILESTONE PAYMENTS UP TO $860 MILLION ASSOCIATED WITH
DEVELOPMENT
* HANMI RETAINS AN OPTION TO COMMERCIALIZE EFINOPEGDUTIDE IN
KOREA
Source text for Eikon: ID:nBw1B8Lnla
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))